Findings

What do systematic reviews say?

188 questions · 193 findings · 30 reviews · Schizophrenia

Sort:Best matchNewest Highest certainty Download CSV

No studies found 54 · 28%GRADE not reported 23 · 11.9%Very low 50 · 25.9%Low 47 · 24.4%Moderate 15 · 7.8%High 4 · 2.1%

RISPERIDONE DEPOT vs QUETIAPINE

Adverse events: Specific: Mean (SD) weight increase in kg ‐ long term · patients with schizophrenia

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 666 participants
Low

RISPERIDONE DEPOT vs ARIPIPRAZOLE

Relapse · patients with schizophrenia

RISPERIDONE DEPOT showed no clear difference in global state: Relapse (any reason) ‐ long term Assessed by 5 blinded… compared with ORAL ARIPIPRAZOLE (low certainty).

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
RR 1.05 [0.83, 1.33]
1 study · 349 participants
Low

RISPERIDONE DEPOT vs ARIPIPRAZOLE

Clinical response: mean score/change in mental state: mean PANSS total score (high = poor) · patients with schizophrenia

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 349 participants
Low

RISPERIDONE DEPOT vs ARIPIPRAZOLE

Leaving the study early · patients with schizophrenia

It is very uncertain whether RISPERIDONE DEPOT changes leaving the study early: Any reason ‐ long term compared with ORAL ARIPIPRAZOLE (very low certainty).

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
RR 0.83 [0.53, 1.3]
2 studies · 723 participants
Very low

RISPERIDONE DEPOT vs OLANZAPINE

Relapse · patients with schizophrenia

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

RISPERIDONE DEPOT vs OLANZAPINE

Clinical response: mean score/change in mental state: mean PANSS total score (high = poor) · patients with schizophrenia

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 361 participants
Low

RISPERIDONE DEPOT vs OLANZAPINE

Leaving the study early · patients with schizophrenia

RISPERIDONE DEPOT may leads to higher leaving the study early: Any reason ‐ long term compared with ORAL OLANZAPINE (low certainty).

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
RR 1.32 [1.1, 1.58]
1 study · 618 participants
Low

RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)

Relapse · patients with schizophrenia

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)

Leaving the study early: lack of efficacy ‐ long term · patients with schizophrenia

RISPERIDONE DEPOT may leads to lower leaving the study early: lack of efficacy ‐ long term compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (low certainty).

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
RR 0.6 [0.45, 0.81]
1 study · 749 participants
Low

RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)

Weight gain · patients with schizophrenia

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 2350 participants
Low

RISPERIDONE DEPOT vs ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE)

Adverse events: Any glucose‐related ‐ medium/long term · patients with schizophrenia

RISPERIDONE DEPOT showed no clear difference in adverse events: Any glucose‐related ‐ medium/long term compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (low certainty).

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
RR 1.79 [0.89, 3.61]
3 studies · 2413 participants
Low

RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS

Relapse · patients with schizophrenia

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS

Clinical response: mean score/change in mental state: mean PANSS total score (high = poor) · patients with schizophrenia

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 43 participants
Low

RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS

Leaving the study early · patients with schizophrenia

RISPERIDONE DEPOT may leads to higher leaving the study early for any reason ‐ long term compared with TYPICAL DEPOT ANTIPSYCHOTICS (low certainty).

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
RR 3.05 [1.12, 8.31]
1 study · 62 participants
Low

RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS

Adverse events: related to movement disorder, weight gain, prolactin levels and glucose metabolism ‐ medium/long term ‐ not reported · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS

Relapse · patients with schizophrenia

It is very uncertain whether RISPERIDONE DEPOT changes global state: Relapse (any reason) ‐ long term Number of… compared with GENERAL ORAL ANTIPSYCHOTICS (very low certainty).

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
RR 2.13 [0.84, 5.43]
1 study · 63 participants
Very low

RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS

Mental state ‐ improvement · patients with schizophrenia

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS

Leaving the study early · patients with schizophrenia

RISPERIDONE DEPOT showed no clear difference in leaving the study early: Any reason ‐ long term compared with GENERAL ORAL ANTIPSYCHOTICS (moderate certainty).

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
RR 1.24 [0.98, 1.57]
2 studies · 467 participants
Moderate

CHLORPROMAZINE vs OLANZAPINE

Relapse · patients with schizophrenia

It is very uncertain whether CHLORPROMAZINE changes relapse: long term (over 12 months) compared with OLANZAPINE (very low certainty).

1 finding from 1 review

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes only
RR 1.5 [0.46, 4.86]
1 study · 70 participants
Very low

FLUPHENAZINE (ORAL) vs RISPERIDONE

Clinically important change in life skills (long term) ‐ not reported · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Fluphenazine (oral) versus atypical antipsychotics for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found